| 1 |
34448208 | The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. | 2022 Feb |
1 |
| 2 |
34668637 | Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom. | 2022 Feb |
1 |
| 3 |
34775781 | Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. | 2022 Feb 22 |
1 |
| 4 |
34866306 | Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial. | 2022 Apr |
1 |
| 5 |
34997102 | Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. | 2022 Jan 7 |
1 |
| 6 |
35059245 | Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control. | 2022 Jan |
2 |
| 7 |
35101924 | Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. | 2022 Jan |
1 |
| 8 |
35134170 | Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants. | 2022 May 17 |
1 |
| 9 |
35175551 | Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. | 2022 Mar |
1 |
| 10 |
35194917 | Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. | 2022 Jun |
1 |
| 11 |
35373878 | Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials. | 2022 Apr 4 |
1 |
| 12 |
35491520 | Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study. | 2022 May 1 |
1 |
| 13 |
33292155 | Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues. | 2021 |
1 |
| 14 |
33300091 | Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57). | 2021 Jan |
1 |
| 15 |
33400403 | Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort. | 2021 May |
2 |
| 16 |
33565209 | Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. | 2021 Jun |
1 |
| 17 |
33581878 | Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD. | 2021 Feb |
1 |
| 18 |
33818009 | Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes. | 2021 May |
2 |
| 19 |
33835520 | Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials. | 2021 Nov |
2 |
| 20 |
33854754 | Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. | 2021 |
2 |
| 21 |
33864629 | Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis. | 2021 May |
3 |
| 22 |
34098057 | Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials. | 2021 Jul |
3 |
| 23 |
34135013 | Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. | 2021 Jul |
1 |
| 24 |
34217774 | Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. | 2021 Aug |
1 |
| 25 |
34745006 | Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. | 2021 |
1 |
| 26 |
32910778 | Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. | 2020 Sep |
1 |
| 27 |
30786725 | Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. | 2019 Apr 23 |
1 |
| 28 |
27459537 | GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome. | 2016 Oct |
1 |
| 29 |
25382096 | GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. | 2014 Nov |
1 |